TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27010235

Group type: EXPERIMENTAL
Intervention: Revexepride 0.02 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Revexepride 0.1 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Revexepride 0.5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All treatment groups (including placebo)
Number of subjects: 80
Study: 24778598

Group type: EXPERIMENTAL
Intervention: LMA with cuff pressure limiting 25 cmH₂O (L group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LMA with cuff pressure limiting 60 cmH₂O (H group)
Number of subjects: 20
Study: 22541443

Group type: EXPERIMENTAL
Intervention: Suggestion-/conditioning-enhanced placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 17
Study: 19816415

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10742
Study: 18612090

Group type: EXPERIMENTAL
Intervention: MTCC qigong program (8 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study: 16098116

Group type: EXPERIMENTAL
Intervention: Biotène Oralbalance (OB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BioXtra (BX)
Number of subjects: 20
Study: 12065273

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10770345

Group type: EXPERIMENTAL
Intervention: 500 kcal daily of caloric supplement with peptides and medium-chain triglycerides plus a multivitamin and mineral supplement
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: 500 kcal of a caloric supplement with whole protein and long-chain triglycerides plus a multivitamin and mineral supplement
Number of subjects: 536

Group type: COMPARATOR
Intervention: Multivitamin and mineral supplement only
Number of subjects: 536
Study: 8914032

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 409
Study: 1678798

Group type: EXPERIMENTAL
Intervention: Porcine insulin (2.5 mU.kg‐1, min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Human insulin (2.5 mU.kg‐1, min‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Porcine insulin and Human insulin
Number of subjects: 7
Study: 6881419

Group type: EXPERIMENTAL
Intervention: Ornidazole 2 g in two equal doses
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g in two equal doses
Number of subjects: 72
Study: 30326827

Group type: EXPERIMENTAL
Intervention: χ2‐based imbalance measures for categorical variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Area between the empirical cumulative distribution functions or the largest difference in the three pairs of quartiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (symmetrised) Kullback‐Leibler divergence
Number of subjects: 0
Study: 27788949

Group type: EXPERIMENTAL
Intervention: Pelvic nodes and prostate radiation therapy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Prostate-only radiation therapy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Pelvic nodes radiation therapy (in low-risk subgroup)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Pelvic irradiation (in patients with <15% risk of lymph node involvement)
Number of subjects: 446
Study: 24576395

Group type: EXPERIMENTAL
Intervention: Immediate educational curriculum (n = 166)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Delayed educational curriculum (n = 154)
Number of subjects: 320
Study: 22775347

Group type: EXPERIMENTAL
Intervention: Liberal transfusion practice (ratio of intraoperative RBC transfusion to blood loss equal to or above the median)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Restrictive transfusion practice (ratio of intraoperative RBC transfusion to blood loss below the median)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Liberal transfusion practice
Number of subjects: 224

Group type: COMPARATOR
Intervention: Restrictive transfusion practice
Number of subjects: 224
Study: 19879166

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional surgery (sapheno-femoral ligation and stripping)
Number of subjects: 93
Study: 17272375

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) group received a biopsychosocial treatment including cognitive behavioral skills training and biofeedback.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nonintervention (NI) group received treatment as usual (biopsychosocial treatment).
Number of subjects: 96
Study: 16055825

Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy (6 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 12708702

Group type: EXPERIMENTAL
Intervention: Small dose pulsed betamethasone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Need based oral steroids
Number of subjects: 0
Study: 10460365

Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sequential CT
Number of subjects: 48
Study: 9097788

Group type: EXPERIMENTAL
Intervention: Macular grid photocoagulation
Number of subjects: 155

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 155
Study: 2564772

Group type: EXPERIMENTAL
Intervention: Applied tension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Applied relaxation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of applied tension and applied relaxation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 778775

Group type: EXPERIMENTAL
Intervention: Experimental physical therapy program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control physical therapy program
Number of subjects: 24
Study: 31821506

Group type: EXPERIMENTAL
Intervention: docetaxel, cyclophosphamide and trastuzumab
Number of subjects: 103

Group type: COMPARATOR
Intervention: 5‐fluorouracil, epirubicin and cyclophosphamide followed by docetaxel, cyclophosphamide and trastuzumab
Number of subjects: 103

Group type: COMPARATOR
Intervention: docetaxel, cyclophosphamide and trastuzumab followed by 5‐fluorouracil, epirubicin and cyclophosphamide
Number of subjects: 103
Study: 30527595

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 106

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 106
Study: 27102504

Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowering baseline and peak heart rate using ivabradine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotropic incompetence (CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-rate pacing
Number of subjects: 0
Study: 23551592

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation (PD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Laparoscopic Heller myotomy with partial fundoplication
Number of subjects: 92
Study: 24487989

Group type: EXPERIMENTAL
Intervention: Aroma massage performed three times a week for 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no aroma massage)
Number of subjects: 54
Study: 20434403

Group type: EXPERIMENTAL
Intervention: Immediate surgery and best medical therapy
Number of subjects: 366

Group type: COMPARATOR
Intervention: Best medical therapy alone
Number of subjects: 366
Study: 18215153

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa (LC) with unchanged dosage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Levodopa-carbidopa (LC) with reduced dosage by 15-25%
Number of subjects: 39
Study: 17030687

Group type: EXPERIMENTAL
Intervention: ISIS 301012 (50 to 400 mg, single dose followed by 4-week multiple dosing)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12747268

Group type: EXPERIMENTAL
Intervention: 10 mg prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10824072

Group type: EXPERIMENTAL
Intervention: Chest compression alone
Number of subjects: 520

Group type: COMPARATOR
Intervention: Chest compression plus mouth-to-mouth ventilation
Number of subjects: 520
Study: 8730339

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (T/S) 2 x 960 mg/day in initial phase WG
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (T/S) 2 x 960 mg/day in generalized WG (group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No further treatment after standard therapy (group B)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (T/S) plus low-dose prednisone (group C)
Number of subjects: 72
Study: 8166061

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Felodipine and Nifedipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 24
Study: 3400062

Group type: EXPERIMENTAL
Intervention: Fatigued state (less than 4 hours of sleep: mean, 2.0 +/- 1.5 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rested state (more than 4 hours of sleep: mean, 6.5 +/- 1.0 hours)
Number of subjects: 42
Study: 31792945

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 250

Group type: COMPARATOR
Intervention: R-CVP
Number of subjects: 250
Study: 31378995

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 750
Study: 28400411

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonobese subjects (control)
Number of subjects: 23
Study: 28004493

Group type: EXPERIMENTAL
Intervention: Intravenous hydration (IVH)
Number of subjects: 759

Group type: COMPARATOR
Intervention: Nasogastric hydration (NGH)
Number of subjects: 759
Study: 23519371

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Volume-matched saline (placebo)
Number of subjects: 36
Study: 22037341

Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 36
Study: 20635603

Group type: EXPERIMENTAL
Intervention: Manipulation under suprascapular nerve block and intraarticular local anesthesia with Methyl prednisolone acetate
Number of subjects: 31
Study: 17560702

Group type: EXPERIMENTAL
Intervention: Transactional sex with casual partners
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Transactional sex with main girlfriends
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Predictors of transactional sex
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Perpetration of gender-based violence
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: HIV prevention interventions
Number of subjects: 1288
Study: 15289018

Group type: COMPARATOR
Intervention: Mitoxantrone and etoposide (MVP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mitoxantrone and etoposide with Cyclosporin A (CsA)
Number of subjects: 80
Study: 11318048

Group type: EXPERIMENTAL
Intervention: Large-scale fragments presented early in processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-scale fragments presented late in processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common feature fragments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global-to-local processing
Number of subjects: 0
Study: 8790670

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pyrimethamine-sulfadoxine (P-S)
Number of subjects: 92
Study: 1299597

Group type: EXPERIMENTAL
Intervention: 200 mg of amineptine
Number of subjects: 169

Group type: COMPARATOR
Intervention: 20 mg of fluoxetine
Number of subjects: 169
Study: 6367750

Group type: EXPERIMENTAL
Intervention: D-penicillamine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (D-penicillamine and hydroxychloroquine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30659035

Group type: EXPERIMENTAL
Intervention: SpO 2 target of 88%-92%
Number of subjects: 2

Group type: COMPARATOR
Intervention: SpO 2 target of ≥96%
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Comparison of standard critical care outcome measures between the two intervention groups
Number of subjects: 2
Study: 30101851

Group type: EXPERIMENTAL
Intervention: Febuxostat (urate-lowering agent)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 200
Study: 25316503

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 50 mg orally twice a day for 2 weeks before operation and maintained for an extra week postoperatively
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA)
Number of subjects: 95
Study: 24566233

Group type: EXPERIMENTAL
Intervention: ICD implantation for primary prevention of sudden cardiac death (PPSCD)
Number of subjects: 1863

Group type: COMPARATOR
Intervention: No ICD implantation but had class I indications
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: Overall ICD utilization rate (UR)
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: ICD UR for males
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: ICD UR for females
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: ICD UR for whites
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: ICD UR for blacks
Number of subjects: 1863
Study: 22496459

Group type: EXPERIMENTAL
Intervention: Outreach program (academic detailing and online tools)
Number of subjects: 3989
Study: 19950088

Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg orally as the initial therapy, with an additional dose of 300 mg after eight hours if needed.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Quinidine (1 mg digoxin IV followed by oral loading of 400 mg followed by 200 mg every two hours).
Number of subjects: 81
Study: 17321397

Group type: EXPERIMENTAL
Intervention: Verisyse IOL implanted under the iris (Group B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Verisyse IOL implanted over the iris (Group A)
Number of subjects: 27
Study: 15179440

Group type: EXPERIMENTAL
Intervention: COX‐2‐selective inhibitor rofecoxib 25 mg daily for 4 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: COX‐2‐selective inhibitor rofecoxib
Number of subjects: 76
Study: 11453892

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg twice daily for 7 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg twice daily for 7 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg twice daily for 7 days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily for 7 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: In vitro incubations with propranolol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: In vitro incubations with nadolol and metoprolol
Number of subjects: 51
Study: 9728825

Group type: EXPERIMENTAL
Intervention: Isoproterenol (IV injections)
Number of subjects: 36
Study: 9155503

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (L, 5.5 g mixed fat/meal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderately high-fat meal (M, 33 g mixed fat/meal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderately high-fat lunch after fasting (NM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fatty breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fatty lunch
Number of subjects: 12
Study: 2654171

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), 100 mg/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), 300 mg/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 19-nortestosterone decanoate (ND), 100 mg/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 19-nortestosterone decanoate (ND), 300 mg/week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 893246

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 0
Study: 31932487

Group type: EXPERIMENTAL
Intervention: Local anesthetic (LA) exposure
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LA dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LA volume
Number of subjects: 180
Study: 31165574

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 27477110

Group type: EXPERIMENTAL
Intervention: OFD with autologous platelet-rich fibrin (PRF)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: OFD with titanium platelet-rich fibrin (TPRF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 38
Study: 25588930

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MPH-SR) 18 to 54 mg/day for 10 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 56
Study: 24006963

Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Smokers (MTS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Interactive Learning for Smokers (ILS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MTS
Number of subjects: 55
Study: 21801539

Group type: EXPERIMENTAL
Intervention: Presentation of treatment benefit using absolute terms
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Presentation of treatment harm in relative terms
Number of subjects: 393
Study: 19426973

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 100
Study: 16942416

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (group T) - patients reported three times weekly via a secure Internet site.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual clinical care (group C) - standard care without telemedicine.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (group T)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual clinical care (group C)
Number of subjects: 36
Study: 15573017

Group type: EXPERIMENTAL
Intervention: Lavender therapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Relaxing music therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lemon therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Preferred music therapy
Number of subjects: 8
Study: 11388525

Group type: EXPERIMENTAL
Intervention: Large LMA (size 5 in males, size 4 in females)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Small LMA (size 4 in males, size 3 in females)
Number of subjects: 258
Study: 9431839

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg single dose
Number of subjects: 12
Study: 8493214

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin combined with ifosfamide and 5-fluorouracil
Number of subjects: 34
Study: 3686263

Group type: EXPERIMENTAL
Intervention: Pipemidic acid (Septidron; Ethimed) for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrofurantoin for 10 days
Number of subjects: 60
Study: 29653338

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 27336797

Group type: EXPERIMENTAL
Intervention: 8-week body mass-based squat exercise training (100 reps/day, 45 sessions)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 8-week body mass-based squat exercise training
Number of subjects: 52
Study: 25759248

Group type: EXPERIMENTAL
Intervention: Intervention prompt group
Number of subjects: 3213

Group type: EXPERIMENTAL
Intervention: Intervention no-prompt group
Number of subjects: 3213

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 3213
Study: 22749632

Group type: EXPERIMENTAL
Intervention: RT + CT (radiation therapy plus cisplatin, 100 mg/m² i.v. on days 1, 22, and 43)
Number of subjects: 410

Group type: COMPARATOR
Intervention: RT (radiation therapy, 60 Gy in 6 weeks)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 410

Group type: COMPARATOR
Intervention: RT
Number of subjects: 410
Study: 20601395

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 150
Study: 18327362

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.02 mg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 102
Study: 16676597

Group type: EXPERIMENTAL
Intervention: Intermittent pulse itraconazole (A group)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Continuous terbinafine (B group)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Intermittent terbinafine (C group)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Compliance with doctors' order
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Noncompliance with doctors' order
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Factors influencing compliance
Number of subjects: 330
Study: 12181245

Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg p.o. b.i.d. for 12 months
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg p.o. b.i.d. for 12 months
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg b.i.d. plus tamoxifen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg b.i.d. plus tamoxifen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg b.i.d.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg b.i.d.
Number of subjects: 63